Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with altered hepatic lipid composition. Animal studies suggest that the hepatic ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) contributes to steatogenesis and inflammation. This ratio may be influenced by dysregulation of the PE N-methyltransferase (PEMT) pathway or by a low-choline diet. Alterations in the liver may also influence lipid composition in circulation such as in erythrocytes, which therefore may have utility as a biomarker of hepatic disease. Currently, no study has assessed both liver and erythrocyte PC/PE ratios in NAFLD. The aim of this study was to compare the PC/PE ratio in the liver and erythrocytes of patients with simple steatosis (SS) or nonalcoholic steatohepatitis (NASH) with that of healthy controls. PC and PE were measured by mass spectrometry in 28 patients with biopsy-proven NAFLD (14 SS, 14 NASH) and 9 healthy living liver donors as controls. The hepatic PC/PE ratio was lower in SS patients (median [range]) (1.23 [0.27–3.40]) and NASH patients (1.29 [0.77–3.22]) compared with controls (3.14 [2.20–3.73]); both p < 0.001) but it was not different between SS and NASH. PC was lower and PE higher in the liver of SS patients compared with controls, whereas in NASH patients only PE was higher. The PC/PE ratio in erythrocytes was also lower in SS and NASH patients compared with controls because of lower PC in both patient groups. PE in erythrocytes was not different among the groups. In conclusion, NAFLD patients have a lower PC/PE ratio in the liver and erythrocytes than do healthy controls, which may play a role in the pathogenesis. The underlying mechanisms require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Assessment of liver biopsies according to Brunt et al. (1999) and Kleiner et al. (2005) a Steatosis grading: 0, <5%; 1, 5 – 33%; 2, >33-66%; 3, >66% b Fibrosis staging in NASH: 1, Zone 3 perivenular perisinusoidal/pericellular fibrosis, focal or extensive; 2, as grade 1 with focal or extensive…”
BackgroundMethodNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 4×
“The Brunt's system was used to assess the degree of steatosis, inflammation, and fibrosis in NAFLD (Brunt et al. 1999).”
BackgroundMethodInfluentialA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 7×
“…studies have shown that the hepatic and plasma fatty acid composition is altered in patients with NAFLD compared to controls (Araya et al. 2004, Puri et al. 2007, Allard et al. 2008, Kotronen et al. 2009, Puri et al. 2009), with a reduction in long-chain polyunsaturated fatty acids (PUFA), and…”
BackgroundResultInfluentialCholine: an essential nutrient for public health
Zeisel, S. H., & da Costa, K.-A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00246.x · Cited by 1,062
Choline: Critical Role During Fetal Development and Dietary Requirements in Adults
Zeisel, S. H. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111156 · Cited by 741 · cited 1×
“PC biosynthesis is necessary for normal very low density lipoprotein secretion from hepatocytes (Zeisel 2006), hence, a reduction in PC, e.g. through choline deficient diets, might lead to hepatic steatosis (Zeisel 2006, Li and Vance 2008).”
BackgroundARAYA, J., RODRIGO, R., VIDELA, L. A., THIELEMANN, L., ORELLANA, M., PETTINELLI, P., & PONIACHIK, J. (2004) · Clinical Science · doi:10.1042/cs20030326 · Cited by 700
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655 · cited 2×
“…composition is altered in patients with NAFLD compared to controls (Araya et al. 2004, Puri et al. 2007, Allard et al. 2008, Kotronen et al. 2009, Puri et al. 2009), with a reduction in long-chain polyunsaturated fatty acids (PUFA), and increased monounsaturated fatty acids being the most…”
BackgroundThe role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314 · cited 1×
“NAFLD is considered to be the hepatic manifestation of the metabolic syndrome (Musso et al. 2008) and is associated with profound changes in lipid metabolism (Musso et al. 2009, Tessari et al. 2009).”
Allard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.009 · Cited by 247 · cited 4×
“Control groups in other studies underwent e.g. elective antireflux or unspecified abdominal surgeries (Araya et al. 2004, Puri et al. 2007) or had a liver biopsy for elevated liver enzymes (Allard et al. 2008) and therefore their tissue might not reflect completely healthy conditions.”
BackgroundSelf-citation
Cited by
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Phosphatidylethanolamine Metabolism in Health and Disease
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2015.10.001 · Cited by 526
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70
Metadata
- Authors
- Arendt, B. M., Ma, D. W. L., Simons, B., Noureldin, S. A., Therapondos, G., Guindi, M., Sherman, M., & Allard, J. P.
- Venue
- Applied Physiology, Nutrition, and Metabolism
- Publisher
- Canadian Science Publishing
- Published
- 2013-03
- Volume
- 38
- Issue
- 3
- Pages
- 334-340
- ISSN
- 1715-5312 (ISSN-L)
- 1715-5320
- OpenAlex
- W1759699758
- Cited by
- 152
- References
- 11
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.